BHST

#4305
BioHarvest Sciences Inc. - Common Stock
1.9 0 USD
-0.01%
Market Price
Sektor: Konjunkturunabhängige Konsumgüter
Basis: USD
Gewinnwährung: USD
Tagesspanne
1.90
1.90
Jahresspanne
1.82
4.91
Tagesänderung
-1.04%
Monatliche Änderung
-12.44%
6 month change
-56.92%
Jahresänderung
-59.40%
Vorheriger Schlusskurs
1.9 2
Open
1.9 0
Tief
1.9 0
Hoch
1.9 0
Volumen
2
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
BIOHARVEST SCIENCES INC. current report, Q3 FY2026
6-K
Current report, Q3 FY2026
BIOHARVEST SCIENCES INC. current report, Q3 FY2026
6-K
Current report, Q3 FY2026
BIOHARVEST SCIENCES INC. current report, Q3 FY2026
6-K
Current report, Q3 FY2026
BIOHARVEST SCIENCES INC. current report, Q3 FY2026
6-K
Current report, Q3 FY2026
BIOHARVEST SCIENCES INC. current report, Q3 FY2026
6-K
Current report, Q3 FY2026
BIOHARVEST SCIENCES INC. current report, Q3 FY2026
6-K
Current report, Q2 FY2026
BIOHARVEST SCIENCES INC. current report, Q2 FY2026
6-K
Current report, Q2 FY2026
BIOHARVEST SCIENCES INC. current report, Q2 FY2026
6-K
Current report, Q2 FY2026
BIOHARVEST SCIENCES INC. current report, Q2 FY2026
6-K
Current report, Q2 FY2026
BIOHARVEST SCIENCES INC. current report, Q2 FY2026
6-K

BIOHARVEST SCIENCES INC. current report, Q1 FY2025

Full document

Business Context and Reporting Period

Company: BioHarvest Sciences Inc.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of March 2025
Principal Executive Offices: Vancouver, British Columbia, Canada
Reporting Standard: Form 40-F

Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 6-K serves primarily as a vehicle to submit exhibits and certifications rather than a financial results report.

Material Changes and Exhibits

The filing includes the submission of several agreements and certifications as exhibits:

  • Certifications: Form 52-109F1 Annual Filing Certifications signed by the CEO and CFO.
  • Strategic Agreements: Agreements dated March 31, 2024, involving BioHarvest Ltd., Enlivex Therapeutics R&D, Ltd., and Eitan On Investment Ltd.
  • Lease Agreements: A lease with Eitan On Investment Ltd. (March 31, 2024) and a new lease with Sugart Ltd. dated January 16, 2025.
  • Government and Media Agreements: A 2007 agreement with the State of Israel Ministry of Agriculture and a 2023 memorandum with TBN Broadcasting of Texas, Inc.
  • Consulting: An Investor Relations Consulting Agreement with MZHCI, LLC dated February 15, 2024.

Guidance, Outlook, and Risks

The filing text does not provide specific guidance, outlook, management commentary, or a discussion of risks and contingencies. Portions of certain exhibits have been redacted in compliance with Regulation S-K.

Key Facts for Investor Verification

  • Verify the financial impact of the new lease agreement with Sugart Ltd. effective January 16, 2025.
  • Review the full text of the March 31, 2024 agreements with Enlivex Therapeutics and Eitan On Investment Ltd. to understand ongoing strategic obligations.
  • Confirm the status of the 2007 agreement with the State of Israel Ministry of Agriculture regarding agricultural research.
  • Note that this filing does not contain updated financial statements; investors should refer to the most recent Form 40-F or 20-F for financial data.